Critical Survey: Outlook Therapeutics (OTLK) vs. Its Rivals
Outlook Therapeutics (NASDAQ: OTLK) is one of 122 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Outlook Therapeutics to similar companies based on the strength of its earnings, dividends, analyst recommendations, profitability, institutional ownership, risk and valuation.
Valuation and Earnings
This table compares Outlook Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Outlook Therapeutics||$3.09 million||-$30.09 million||-0.19|
|Outlook Therapeutics Competitors||$853.15 million||$178.74 million||-0.44|
This is a summary of current ratings and price targets for Outlook Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Outlook Therapeutics Competitors||904||2934||6317||279||2.57|
Outlook Therapeutics currently has a consensus target price of $9.33, suggesting a potential upside of 362.05%. As a group, “Biological products, except diagnostic” companies have a potential upside of 44.46%. Given Outlook Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Outlook Therapeutics is more favorable than its rivals.
This table compares Outlook Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Outlook Therapeutics Competitors||-4,670.94%||-78.62%||-34.79%|
Volatility and Risk
Outlook Therapeutics has a beta of -0.81, suggesting that its share price is 181% less volatile than the S&P 500. Comparatively, Outlook Therapeutics’ rivals have a beta of 1.77, suggesting that their average share price is 77% more volatile than the S&P 500.
Insider & Institutional Ownership
0.8% of Outlook Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 11.5% of Outlook Therapeutics shares are owned by insiders. Comparatively, 16.9% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Outlook Therapeutics rivals beat Outlook Therapeutics on 7 of the 13 factors compared.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.